$253.32
+6.00% past month
Notable price movement
Oct 23, 2026
$253.97-0.10%
Oct 22, 2026
$254.23+2.70%
Comparable listed companies moved -0.16% on average on the day, with 2 of 5 falling and 3 rising . The company's 2.70% gain was therefore not shared by the cohort, which was close to flat .
Oct 21, 2026
$247.55-0.49%
The Motley Fool reported that L3Harris won an $876 million Next Generation Jamming contract tied to a U.S. Navy program . Shares still closed down 0.49%, while comparable listed companies rose 0.89% on average . The decline therefore ran against the group's move .
Oct 20, 2026
$248.77+2.02%
L3Harris rose 2.02%, while comparable listed companies moved +0.53% on average, with 3 of 5 rising and 2 falling . The gain was therefore larger than the cohort's average move.
Oct 19, 2026
$243.84-1.88%
Comparable listed companies in search, detection, navigation, guidance and aeronautical systems fell 0.43% on average, with 3 of 5 lower . The company's 1.88% decline was steeper than the cohort's average move. Northrop Grumman fell 1.77% and DRS fell 0.68%, while Garmin rose 0.48% .
Oct 16, 2026
$248.51+3.33%
LHX rose 3.33% on a day when comparable listed companies moved -0.66% on average, with 4 of 5 falling . The gain was therefore not shared by the cohort as a whole, although one peer, NOC, rose 4.05% . Volume was 2.1x the trailing 20-session average, and the session traded in a range of 2.7% of the low .
Oct 15, 2026
$240.50+1.26%
L3Harris rose 1.26% while comparable listed companies rose 2.22% on average, with all 5 advancing . The move came alongside a gain across the group. Volume was 1.8x the trailing 20-session average . PR Newswire carried an announcement that HGT Law was investigating claims on behalf of shareholders .
Closing prices for LHX. Summaries describe past sessions only and are not advice, a forecast or a recommendation.
Recent news
Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.
Prices and financial data are historical and provided for research only. Not investment advice.